Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo
Important Safety Information | Patient Site
Prescribing Information
    • Why Esperoct®
    • Pharmacology
    • Mechanism of Action
    • Prophylaxis
    • On Demand & Perioperative
    • Safety Profile
    • Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

Indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct® is not indicated for the treatment of von Willebrand disease.

Prescribing Information
Important Safety Information | Patient Site

Talk to us about Esperoct®.

Financial programs and support for patients

Novo Nordisk provides assistance through NovoCare®, a network to help your patients access co-pay savings, product support, and more.


Financial programs and support for patients

Novo Nordisk provides assistance through NovoCare®, a network to help your patients access co-pay savings, product support, and more.


Father and son smiling

NovoCare® is designed for your patients

Patients can access:

  • Product support programs that help with treatment costs
  • Representatives who speak Spanish to better serve them

You can help your patients by calling 1‑844‑668‑6732 or have them contact NovoCare® at NovoCare.com 


NovoCare® can help with:

QuickCheck™ benefits verification
Document with green checkmark icon

Verify your patients' benefits and receive confirmation of coverage. If no coverage is available, names of alternative therapies may be supplied.

Patient Assistance Program (PAP)
Hand holding a heart icon

See if your patients are eligible to receive their treatment free of charge. No registration or monthly fees required.

Eligibility and restrictions apply.

Patient Trial
Program
Medication bag with a heart icon

Find out if your patients qualify to receive a limited supply of Novo Nordisk's product for free.

Eligibility and restrictions apply.

Patient
enrollment form
Form with plus sign icon

Download and complete the patient enrollment form to attest your patient's need for treatment.

Go to resources

Additional resources for patients

Co-pay Assistance Program
website
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Co-pay Assistance Program
Direct your commercially insured patients to our program to find out if they’re eligible for a lower copay with a savings offer.
Visit website

Interim Product Program

Hands holding a plus sign icon

This limited program provides hemophilia therapy to qualifying patients during a coverage gap. Contact a NovoCare® Specialist by calling 1‑844‑668‑6732.

Free Trial Prescription

Esperoct® vial

Help your patients make the switch to Esperoct®. Learn more about Novo Nordisk’s trial prescription and support programs. To learn more about our trial prescription program, please call 1‑844‑668‑6732 to speak with a NovoCare® Specialist.

Questions about the NovoCare® program?

Selected Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
QuickCheck™ is a trademark of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark of Novo Nordisk A/S.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2024 Novo Nordisk All rights reserved. US24ESP00008 August 2024

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials